Variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, brand/generic distinctions, and the practice of medicine contribute to ambiguous interpretations of cross-country pharmaceutical cost comparisons. Here, we report cross-country comparisons that: (i) focus on ten therapeutic classes experiencing patent expiration and loss of exclusivity 2004–2010 in eight industrialized countries; (ii) convert revenues and unit sales to cost per day of treatment and number patient days treated using the World Health Organization’s Defined Daily Dosage metrics; (iii) compare patterns in costs per day of treatment with price index measures based on average price per day of treatment for each molecule computed over all molecule versions; (iv) utilizing econometric methods, model and quantify various factors affecting variations in daily treatment price indexes such as national regulatory and reimbursement policy changes, physician/pharmacy autonomy, and other factors; and (v) simulate changes in expenditures by country and therapeutic class had counterfactual policies been implemented.
Cross-Country Comparisons; Pharmaceutical Costs; Generic Drugs;
- D4: Market Structure and Pricing
- I11: Analysis of Health Care Markets
- I18: Government Policy • Regulation • Public Health
- L11: Production, Pricing, and Market Structure • Size Distribution of Firms
- L65: Chemicals • Rubber • Drugs • Biotechnology
- O34: Intellectual Property and Intellectual Capital
Ernst R. Berndt et Pierre Dubois, « Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010 », IDEI Working Paper, n° 702, mars 2012.
Ernst R. Berndt et Pierre Dubois, « Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010 », TSE Working Paper, n° 12-283, mars 2012.
Ernst R. Berndt et Pierre Dubois, « Impacts of Patent Expiry of Pharmaceutical Treatments in Eight OECD Countries, 2004-2010 », International Journal of the Economics of Business, vol. 23, n° 2, mai 2016, p. 125–147.
International Journal of the Economics of Business, vol. 23, n° 2, mai 2016, p. 125–147